These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 3486038

  • 21. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP, Ottow RT, Eggermont AM, Marquet RL, Sugarbaker PH.
    Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
    [Abstract] [Full Text] [Related]

  • 22. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ, Yang JC, Afreniere RL, Shu SY, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):285-94. PubMed ID: 3108401
    [Abstract] [Full Text] [Related]

  • 23. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R, Malloy B, Sherrod A, Bean P, Girgis E, Mazumder A.
    J Biol Response Mod; 1988 Apr 01; 7(2):140-51. PubMed ID: 3258905
    [Abstract] [Full Text] [Related]

  • 24. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
    Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA.
    J Immunol; 1985 Aug 01; 135(2):1488-97. PubMed ID: 3891854
    [Abstract] [Full Text] [Related]

  • 25. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N, Tanaka R, Yoshida S, Hara N, Saito T.
    Cancer Res; 1988 Apr 15; 48(8):2047-52. PubMed ID: 3258182
    [Abstract] [Full Text] [Related]

  • 26. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 27. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K, Pellis NR, Kahan BD.
    Cancer Res; 1988 Jan 01; 48(1):101-8. PubMed ID: 3257158
    [Abstract] [Full Text] [Related]

  • 28. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
    Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA.
    J Immunol; 1986 Dec 01; 137(11):3675-80. PubMed ID: 3491145
    [Abstract] [Full Text] [Related]

  • 29. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
    Schwarz RE, Vujanovic NL, Hiserodt JC.
    Cancer Res; 1989 Mar 15; 49(6):1441-6. PubMed ID: 2784350
    [Abstract] [Full Text] [Related]

  • 30. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA.
    Cancer Res; 1988 Aug 01; 48(15):4409-16. PubMed ID: 3260537
    [Abstract] [Full Text] [Related]

  • 31. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
    Eggermont AM, Sugarbaker PH.
    Cancer Detect Prev; 1990 Aug 01; 14(4):483-90. PubMed ID: 2224911
    [Abstract] [Full Text] [Related]

  • 32. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
    Pope BL, Chourmouzis E, Sigindere J, MacIntyre JP, Capetola RJ, Lau CY.
    Cell Immunol; 1993 Apr 01; 147(2):302-12. PubMed ID: 8453674
    [Abstract] [Full Text] [Related]

  • 33. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM, Blazar BR, Bach FH, Ochoa AC.
    J Immunol; 1989 Feb 15; 142(4):1383-94. PubMed ID: 2521662
    [Abstract] [Full Text] [Related]

  • 34. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
    Lala PK, Parhar RS.
    Cancer Res; 1988 Mar 01; 48(5):1072-9. PubMed ID: 3124954
    [Abstract] [Full Text] [Related]

  • 35. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA, Mulé JJ.
    Surgery; 1985 Sep 01; 98(3):437-44. PubMed ID: 3898451
    [Abstract] [Full Text] [Related]

  • 36. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ, Silver HK, Kong S.
    Cancer Res; 1990 Aug 15; 50(16):4906-10. PubMed ID: 2379154
    [Abstract] [Full Text] [Related]

  • 37. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO, Gregg IC, Green I.
    Cancer Res; 1987 Feb 01; 47(3):723-9. PubMed ID: 3492265
    [Abstract] [Full Text] [Related]

  • 38. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR, Klarnet JP, Peace DJ, Cheever MA, Badger CC, Bernstein ID, Greenberg PD.
    Cancer Res; 1990 Sep 01; 50(17):5421-5. PubMed ID: 2386946
    [Abstract] [Full Text] [Related]

  • 39. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA.
    Cancer Res; 1988 Dec 15; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [Abstract] [Full Text] [Related]

  • 40. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
    Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D, Fefer A.
    Cancer Res; 1989 Jan 01; 49(1):235-40. PubMed ID: 2783243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.